Antibiotics

---

Antibiotics are a class of antimicrobial substances used to treat and prevent bacterial infections. These compounds work by targeting specific biological processes in bacteria—such as cell wall synthesis, protein production, or DNA replication—that are either absent or fundamentally different in eukaryotic cells (such as those of humans). By selectively inhibiting these processes, antibiotics can either kill bacteria outright (bactericidal action) or inhibit their growth and reproduction (bacteriostatic action), allowing the host's immune system to eliminate the remaining pathogens. The discovery and deployment of antibiotics in the early 20th century marked one of the most significant advancements in medical history. Before the "antibiotic era," common infections—such as strep throat, pneumonia, or infected wounds—could be fatal. The introduction of these drugs shifted the paradigm of medicine from palliative care (managing symptoms) to curative treatment, drastically increasing global life expectancy and enabling complex medical procedures such as organ transplants and chemotherapy, which rely on the ability to control opportunistic infections. While highly effective, the utility of antibiotics is currently threatened by the emergence of antimicrobial resistance (AMR). Because bacteria reproduce rapidly and can exchange genetic material through horizontal gene transfer, they can evolve mechanisms to neutralize the drug's effect. This evolutionary pressure has led to the rise of "superbugs," strains of bacteria that are resistant to multiple classes of antibiotics, creating a critical public health challenge that requires the development of new drug classes and more stringent stewardship of existing ones.

Mechanism of Action

Antibiotics are categorized based on their chemical structure and the specific cellular target they attack. The goal is "selective toxicity," meaning the drug harms the pathogen without harming the host.

Many bacteria possess a rigid cell wall made of peptidoglycan, which protects them from osmotic pressure. Beta-lactams, such as penicillin and cephalosporins, inhibit the enzymes (penicillin-binding proteins) that cross-link the peptidoglycan layers. This weakens the cell wall, leading to osmotic lysis—the cell essentially bursts due to internal pressure.

Bacteria utilize ribosomes to translate mRNA into proteins. Antibiotics like tetracyclines, aminoglycosides, and macrolides bind to the 30S or 50S subunits of the bacterial ribosome. Because bacterial ribosomes differ in structure from human ribosomes, these drugs can selectively halt the production of essential bacterial proteins.

Some antibiotics target the enzymes responsible for DNA replication or RNA transcription. Fluoroquinolones, for example, inhibit DNA gyrase and topoisomerase IV, enzymes that manage the supercoiling of DNA. Without these, the bacteria cannot replicate their genome, leading to cell death.

Certain antibiotics block the synthesis of essential nutrients. Sulfonamides (sulfa drugs) act as competitive inhibitors for the enzyme dihydropteroate synthase, preventing the bacteria from synthesizing folic acid, a precursor necessary for nucleotide production.

Historical Development

The history of antibiotics is often divided into the pre-antibiotic era and the modern era, catalyzed by the discovery of penicillin.

While various cultures used molds and plant extracts for healing for millennia, the scientific era began with Paul Ehrlich's search for a "magic bullet" (a compound that could kill a pathogen without harming the host), leading to the development of Salvarsan for syphilis in 1909. However, the turning point occurred in 1928 when Alexander Fleming observed that Penicillium notatum mold inhibited the growth of Staphylococcus bacteria. It was not until the late 1930s and early 1940s that Howard Florey and Ernst Chain succeeded in purifying penicillin for clinical use, coinciding with the needs of World War II.

From the 1940s to the 1960s, scientists screened soil samples worldwide, leading to the discovery of streptomycin (the first drug effective against tuberculosis) and tetracyclines. This period saw the identification of most of the major antibiotic classes used today, as researchers realized that many fungi and soil bacteria (such as Streptomyces) naturally produce antibiotics to compete for resources in their environment.

Classification and Spectrum

Antibiotics are further classified by their "spectrum," which refers to the range of bacterial species they can affect.

These are effective against only a few types of bacteria. For example, penicillin G is primarily effective against Gram-positive bacteria. Narrow-spectrum drugs are often preferred by clinicians because they minimize "collateral damage" to the commensal microbiome (the beneficial bacteria in the gut and skin).

These act against a wide range of both Gram-positive and Gram-negative bacteria. While useful when the causative agent of an infection is unknown (empiric therapy), their prolonged use can lead to opportunistic infections, such as Clostridioides difficile (C. diff), as the drug wipes out the protective healthy flora of the intestines.

Antimicrobial Resistance (AMR)

Resistance occurs when bacteria evolve mechanisms to survive exposure to an antibiotic. This is a classic example of natural selection.

Bacteria employ several strategies to resist antibiotics:

1. Enzymatic Degradation: Producing enzymes like $\beta$-lactamase that break the chemical bonds of the antibiotic.

1. Efflux Pumps: Developing specialized protein pumps that eject the drug from the cell before it can reach its target.

1. Target Modification: Mutating the shape of the target protein (e.g., the ribosome) so the drug can no longer bind.

1. Metabolic Bypass: Developing alternative pathways to produce necessary nutrients, bypassing the step blocked by the drug.

The acceleration of AMR is largely attributed to the overuse and misuse of antibiotics in human medicine and industrial agriculture. When antibiotics are used unnecessarily (e.g., for viral infections like the common cold) or used in sub-lethal doses, they kill the susceptible bacteria and leave behind the resistant ones, which then multiply and spread.

Future Directions and Alternatives

As traditional antibiotic pipelines slow down, researchers are exploring novel strategies to combat resistant infections.

Bacteriophages are viruses that specifically infect and kill bacteria. Unlike antibiotics, phages are highly specific to a single strain of bacteria and can evolve alongside the pathogen, potentially overcoming the issue of resistance.

Recent research involves using CRISPR-Cas9 gene-editing technology to create "programmable" antibiotics. These systems can be delivered into bacteria via phages to specifically target and cleave resistance genes or essential virulence factors within the bacterial genome.

Scientists are developing "antibiotic potentiators"—compounds that do not kill bacteria themselves but inhibit the bacteria's resistance mechanisms (e.g., $\beta$-lactamase inhibitors), thereby restoring the efficacy of older antibiotics.

See also

• Bacteriology
• Microbiome
• Pharmacology
• Zoonosis

References